Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimta LabsBOM:524394 +2.44%84 Days Inventory is 120.53 as of Jun. 2026, which is 4% above its 10-year median of 115.90. GuruFocus rates BOM:524394 with a GF Score™ of 84/100 and a GF Value™ of ₹495.54 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 178 Medical Diagnostics & Research companies, Vimta Labs ranks worse than 73.03% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Vimta Labs's Average Total Inventories for the
three
months ended in Jun. 2026 was ₹299 Mil. Vimta Labs's Cost of Goods Sold for the
three
months ended in Jun. 2026 was ₹227 Mil.
Hence, Vimta Labs's Days Inventory for the
three
months ended in Jun. 2026 was 120.53.
The historical rank and industry rank for Vimta Labs's Days Inventory or its related term are showing as below:
BOM:524394'
s Days Inventory Range Over the Past 10 Years
Min: 73.77 Med: 115.9 Max: 149.76
Current: 120.16
During the past 13 years, Vimta Labs's highest Days Inventory was 149.76. The lowest was 73.77. And the median was 115.90.
BOM:524394's Days Inventory is ranked worse than 73.03% of 178
companies
in the Medical Diagnostics & Research industry
Industry Median: 66.965
vs BOM:524394: 120.16
Vimta Labs's Days Inventory
declined
from Jun. 2025 (121.56) to Jun. 2026 (120.53).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Vimta Labs's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.76.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Vimta Labs's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.27.
Vimta Labs (BOM:524394) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Vimta Labs's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Vimta Labs's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Vimta Labs Days Inventory Related Terms
Vimta Labs Days Inventory Historical Data
* Premium members only.
The historical data trend for Vimta Labs's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524394 vs TMO, DHR, IDXX: Days Inventory Comparison
For the Diagnostics & Research subindustry, Vimta Labs's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimta Labs Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimta Labs's Days Inventory distribution charts can be found below:
* The bar in red indicates where Vimta Labs's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimta Labs (BOM:524394) has a Days Inventory of 120.53 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Vimta Labs and its competitors. This is near median its historical median of 115.90. Over the past decade, Vimta Labs' Days Inventory has ranged from 73.77 to 149.76. According to the industry distribution chart, Vimta Labs ranks #130 out of 178 companies in the Medical Diagnostics & Research industry, placing it in the top 73%.
Is Vimta Labs' Days Inventory too high?
Vimta Labs' current Days Inventory of 120.53 is near median its 10-year median of 115.90. Over the past 10 years, this metric has ranged from a low of 73.77 to a high of 149.76. The Medical Diagnostics & Research industry median Days Inventory is 66.97. Vimta Labs' value of 120.53 is 80% above this industry median. Based on the distribution chart, Vimta Labs ranks #130 out of 178 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Vimta Labs has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vimta Labs' Days Inventory compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimta Labs ranks #130 out of 178 companies for Days Inventory. This places Vimta Labs in the lower half of its industry. The industry median Days Inventory is 66.97. Vimta Labs' value of 120.53 is 80% above this benchmark. Historically, Vimta Labs' own Days Inventory has ranged from 73.77 to 149.76 over the past decade. While the company's 10-year median is 115.90 vs. the industry median of 66.97, Vimta Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 66.97, based on 178 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimta Labs's current Days Inventory of 120.53 is 80% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Vimta Labs and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 66.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimta Labs's current Days Inventory is 120.53, which is near median its own 10-year median of 115.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimta Labs stock overvalued right now?
Based on GuruFocus' analysis, Vimta Labs (BOM:524394) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹495.54, compared to a current price of ₹656.85 — trading 32.6% above its estimated fair value. The current Days Inventory is 120.53, which is near median its 10-year median of 115.90 and 80% above the Medical Diagnostics & Research industry median of 66.97. Vimta Labs' overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Vimta Labs (BOM:524394), the current Days Inventory is 120.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimta Labs (BOM:524394) Overvalued in 2026?
Based on GuruFocus' analysis, Vimta Labs stock appears to be overvalued.
The current stock price of ₹656.85 is trading 32.6% above its estimated GF Value™ of ₹495.54.
GuruFocus considers Vimta Labs to be Significantly Overvalued.
Key valuation signals for BOM:524394:
Days Inventory: 120.53 (near median its 10-year median of 115.90)
GF Value™: ₹495.54 vs. price of ₹656.85 (32.6% above fair value)
Industry Position: 80% above the Medical Diagnostics & Research median (#130 of 178)
No single metric tells the full story. See the BOM:524394 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimta Labs Ltd is a comprehensive contract research and testing organization, providing a wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and many other industries. Its services portfolio includes testing and contract research services in the fields of clinical research, pre-clinical research, clinical diagnostics, biopharma services, analytical testing, research and environmental studies, and Others. It has only one reportable segment namely Contract Research and Testing Services which generates the revenue.
84GF Score
Get the complete analysis for BOM:524394
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524394 has been successfully added to your 
